Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19)

archived

The goal of the IPCAVD Funding Opportunity Announcement (FOA) is to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through CGMP manufacture/testing/product release and into clinical trials. A preclinical research application alone is not sufficient for this announcement. Awards will provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the first 5 years of the award. However, this funding opportunity will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies. Investigators are expected to begin clinical studies no later than year five of the award.

High